Thursday, September 4, 2025

Asking Teens at Risk of Suicide to Name Reasons to Live Can Help Inform Therapy

Hospitalized teenagers at risk of suicide can articulate their own personal reasons for living, which can be an important aspect of safety planning and treatment, according to a report published today in Psychiatric Services.

Ana M. Ugueto, Ph.D., of the University of Texas Health Science Center, and colleagues used retrospective data from the electronic medical records of 211 teenagers (71% female) who were admitted to the adolescent unit of a psychiatric hospital in 2023 for suicidal thoughts or behaviors. As part of the unit’s routine clinical services, staff collected data on demographic characteristics, suicide risk, referral details for individual therapy, and reasons for living.

Responses were varied but were often related to family, friends, and pets as well as the adolescents’ future aspirations. The responses were qualitatively analyzed to determine the most frequently occurring words and identify word-based patterns and contextual factors that indicate what matters to adolescents.

The most frequently occurring words were “my,” “family,” and “friends.” “Mom” was the individual family member mentioned most often, with “siblings” also cited repeatedly—specifically “sister” and “brother.” The most frequently occurring nouns were “family,” “friends,” “future,” “mom,” “life,” “sister,” “siblings,” “goals,” “brother,” and “dog.” Among verbs, “want” and “be” were used most often, typically in combination with life goals or career aspirations, indicating future-oriented thinking.

“This study elucidated the particular importance of key people, which can reveal insights about adolescents’ motivations for living,” Ugueto and colleagues wrote. They noted that the interpersonal theory of suicide highlights thwarted belonging and perceived burdensomeness as important in suicidal behavior. “Reasons for living indicate unique protective factors that may counter risk factors and suggest ways in which youths feel they belong and have a purpose.”

Ugueto and colleagues concluded: “Identification of individualized reasons for living can provide unique insights into who and what is most important to adolescents. Reasons for living can feasibly be used to build rapport, establish therapy goals, and personalize evidence-based treatments, thereby reducing adolescents’ suicidal thoughts and behaviors.”

For related information, see the Psychiatric News article “Adolescent Suicide Rises, With Highest Risk for Black Girls.”




Don't miss out! To learn about newly posted articles in Psychiatric News, please sign up here.

Follow Psychiatric News on X, LinkedIn and Instagram!



Wednesday, September 3, 2025

Semaglutide Lowers Weight, Glucose Levels in Adults With Schizophrenia

Once-weekly semaglutide can help individuals with schizophrenia lose weight and lower their blood glucose levels without adversely affecting their mental health, according to clinical trial findings published today in JAMA Psychiatry.

Ashok A. Ganeshalingam, M.D., of Odense University Hospital in Denmark, and colleagues recruited 154 adults (ages 18 to 60, 57% female) diagnosed with schizophrenia, schizotypal disorder, or schizoaffective disorder; all participants also had prediabetes and a BMI of 27 or higher. Participants were randomized to receive 30 weeks of semaglutide (Ozempic), up to 1 mg/week, or placebo alongside their existing medications. (Note: This trial was supported by private foundations in Denmark, including the Novo Nordisk Foundation. Novo Nordisk is the manufacturer of Ozempic.)

At the end of the trial, patients who took semaglutide lost an average of 9 kg (20 pounds), whereas those on placebo remained at their baseline weight. The patients on semaglutide also showed significant improvements in their metabolic profiles—81% reduced their HbA1c value below 5.7% (the cutoff for prediabetes) compared with 19% of patients in the placebo group.

Behaviorally, there were no significant differences in positive or negative symptom scores between the groups after 30 weeks, nor any differences in their mental health–related quality of life. Gastrointestinal symptoms such as nausea or constipation were more frequent in the semaglutide group, though serious adverse events—most commonly an exacerbation of psychiatric symptoms—were similar between groups. 

Given the observed benefits, “semaglutide should be considered for patients with [schizophrenia], prediabetes, and a BMI of 27 or higher, as the potential for weight loss and prevention of [type 2 diabetes] may justify the economic cost of treatment,” Ganeshalingam and colleagues concluded.

For related information, see the Psychiatric News article “Obesity Expert Advises on Helping Psychiatric Patients Manage Obesity.”

(Image: Getty Images/iStock/aprott)




Don't miss out! To learn about newly posted articles in Psychiatric News, please sign up here.

Follow Psychiatric News on X, LinkedIn and Instagram!



Tuesday, September 2, 2025

APA Releases New Practice Guideline on Delirium

APA has published an all-new clinical practice guideline on the prevention and treatment of delirium. Developed by a multidisciplinary workgroup, the new guideline is intended for use by any clinician who may encounter delirium in their scope of practice.

“Having a psychiatrically informed clinical practice guideline is essential—and has profound psychiatric import—because a diagnosis of delirium excludes pretty much every other psychiatric diagnosis,” said workgroup member Mark A. Oldham, M.D., of the University of Rochester Medical Center.

The practice guideline includes 12 clinical recommendations and three suggestions related to assessment and treatment planning, pharmacological and non-pharmacological interventions, and transitions of care. Among these are the recommendation that antipsychotic medications should not be used to prevent delirium or hasten its resolution. These medications can be used to address neuropsychiatric symptoms of delirium such as agitation, but only if the symptoms cause significant distress and other de-escalation strategies haven’t worked.

Another key message is to ensure that people with or at-risk of delirium receive positive daytime stimulation, such as spending time with family, and the proper nighttime environment to facilitate sleep. “We emphasize these because we recognize that they are not being done consistently,” Oldham said. “We want to drive home, based on really sound data, the importance of these nonpharmacological interventions across the board for promoting healthy cognition while hospitalized.”

Read more about the development of the delirium practice guideline in the September issue of Psychiatric News, available now online. The current issue also includes a Special Report on antidepressant withdrawal, an “Ethics Corner” column on the complicated issue of involuntary hospitalization, and more.




Don't miss out! To learn about newly posted articles in Psychiatric News, please sign up here.

Follow Psychiatric News on X, LinkedIn and Instagram!